Acute Pancreatitis Clinical Trial
Official title:
Phase 2/3 Study of Use of Streptokinase for Enhancement of Percutaneous Drainage of Pancreatic Necrosis
Around 20 per cent of patients with acute pancreatitis develop pancreatic or peripancreatic
necrosis with or without peripancreatic collection.
Percutaneous catheter drainage successfully drains the liquefied component of pancreatic
necrosis while the solid component still remains undrained. This infected solid component of
pancreatic necrosis is probably responsible for failure of percutaneous catheter drainage
which demands surgical debridement.
Streptokinase is a protein secreted by several species of streptococci which can bind and
activate human plasminogen.
In the present study investigators plan to instill streptokinase locally in to the
collections of patients with severe acute pancreatitis via pigtail catheter inorder to
liquefy the solid necrotic component and analyze whether it hastens the drainage and thereby
delays or obviates the need for necrosectomy.
Around 20 per cent of patients with acute pancreatitis develop pancreatic or peripancreatic
necrosis with or without peripancreatic collections. Sterile necrosis can generally be
managed conservatively and the mortality rate is relatively low (12 per cent). Approximately
30 (range 14-62) per cent of patients with necrotizing pancreatitis, however, develop
secondary infections of peripancreatic fluid collection which is associated with sepsis and
organ failure and is an indication for intervention1.
Until recently, the first-choice intervention in patients with infected necrotizing
pancreatitis or sterile necrosis with clinical deterioration (multiple organ failure) has
been open surgical necrosectomy. This approach is associated with considerable morbidity
(34-95 per cent) and mortality (11-39 per cent). In 1998, Freeny and colleagues10 first
described a consecutive series of patients with infected pancreatic necrosis who were
treated primarily with imaging-guided percutaneous catheter drainage (PCD), as an
alternative to primary surgical necrosectomy. The rationale for PCD was to drain the
infected fluid under tension and gain time to improve organ function of these critically ill
patients and thereby delay or avoid surgical necrosectomy. In their retrospective cohort
study, PCD was successful in postponing surgical intervention for a median of 4 weeks and
even obviated the need for surgical necrosectomy in almost half of the patients. In
addition, PCD seems technically feasible in the vast majority of patients with necrotizing
pancreatitis.
In clinical experience, investigators have found that PCD successfully drains the liquefied
component of pancreatic necrosis while the solid component still remains undrained. This
infected solid component of pancreatic necrosis is probably responsible for failure of PCD
which demands surgical debridement.
Streptokinase is a protein secreted by several species of streptococci which can bind and
activate human plasminogen. It is primarily used in clinical practice intravenously as an
effective thrombolytic agent in cases of myocardial infarction and pulmonary
thromboembolism.
The earliest reports on intracavitatory use of Streptokinase and other fibrinolytics were
for empyemas. Later because of beneficial results, their intracavitatory use was extended to
other conditions like liver, retroperitoneal and peritoneal abscesses.
In a phase II study, intracavitatory urokinase has shown to facilitate percutaneous drainage
significantly reduce hospital stay and costs of percutaneous drainage of intra abdominal,
retroperitoneal abscesses.
In the present study investigators plan to instill streptokinase locally in to the
collections of patients with severe acute pancreatitis via pigtail catheter inorder to
liquefy the solid necrotic component and analyze whether it hastens the drainage and thereby
delays or obviates the need for necrosectomy.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05410795 -
Establishment and Verification of Pancreatic Volume Formula Based on Imaging
|
||
Recruiting |
NCT04195347 -
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
|
Phase 1/Phase 2 | |
Completed |
NCT04735055 -
Artificial Intelligence Prediction for the Severity of Acute Pancreatitis
|
||
Completed |
NCT02928718 -
The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations
|
||
Terminated |
NCT02885441 -
Treatment of Acute Pancreatitis With Ketorolac
|
Phase 4 | |
Completed |
NCT02563080 -
Pancreatic Exocrine Insufficiency in Acute Pancreatitis
|
||
Recruiting |
NCT01626911 -
Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis
|
N/A | |
Completed |
NCT01507766 -
The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis
|
Phase 4 | |
Completed |
NCT04901949 -
The Course of Acute Pancreatitis in Patients With Different BMI Groups
|
||
Recruiting |
NCT04814693 -
Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis
|
N/A | |
Completed |
NCT02743364 -
Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis
|
Phase 2 | |
Recruiting |
NCT05281458 -
Early Versus Standard Endoscopic Interventions for Peripancreatic Fluid Collections
|
N/A | |
Not yet recruiting |
NCT04990336 -
Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis
|
N/A | |
Not yet recruiting |
NCT03259880 -
Searching the Best Prognostic Factor in Out Come Evaluation in Patients With Acute Pancreatitis Admitted at Assiut University Hospitals
|
N/A | |
Completed |
NCT02543658 -
Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension
|
Phase 2 | |
Recruiting |
NCT06023771 -
Invasive Intervention of Local Complications of Acute Pancreatitis
|
||
Not yet recruiting |
NCT05501314 -
Remote Home Monitoring Acute Pancreatitis
|
N/A | |
Completed |
NCT02897206 -
Imipenem Prophylaxis in Patients With Acute Pancreatitis
|
Phase 4 | |
Recruiting |
NCT03634787 -
Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis
|
||
Active, not recruiting |
NCT04989166 -
Effect of Nano-curcumin Supplementation in Acute Pancreatitis
|
N/A |